2023. CLINICAL-PATOGENETIC RATIONALE FOR THE USE OF GLYCOSAMINOGLYCANS IN THE TREATMENT OF PATIENTS WITH GLOMERULONEPHRITIS. Art of Medicine. 28, 4 (Dec. 2023), 88–93. DOI:https://doi.org/10.21802/artm.2023.4.28.88.